136 related articles for article (PubMed ID: 9641218)
1. Five-year survival in patients with endometrioid carcinoma of the ovary versus those with serous carcinoma.
Zwart J; Geisler JP; Geisler HE
Eur J Gynaecol Oncol; 1998; 19(3):225-8. PubMed ID: 9641218
[TBL] [Abstract][Full Text] [Related]
2. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
[TBL] [Abstract][Full Text] [Related]
3. Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary.
Geisler JP; Wiemann MC; Miller GA; Geisler HE
Gynecol Oncol; 1996 Mar; 60(3):424-7. PubMed ID: 8774651
[TBL] [Abstract][Full Text] [Related]
4. [Five years survival in patients with endometrioid ovarian cancer versus patients with serous ovarian cancer].
Ivanov S; Batashki I
Akush Ginekol (Sofiia); 2008; 47(5):9-11. PubMed ID: 19227770
[TBL] [Abstract][Full Text] [Related]
5. Transitional cell-like morphology in ovarian endometrioid carcinoma: morphologic, immunohistochemical, and behavioral features distinguishing it from high-grade serous carcinoma.
Karnezis AN; Aysal A; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2013 Jan; 37(1):24-37. PubMed ID: 23108017
[TBL] [Abstract][Full Text] [Related]
6. Neutral mucosubstances as a prognostic indicator in serous and endometrioid carcinomas of the ovary. A morphometrical analysis of saliva-periodic acid-Schiff stain.
Aalto ML
Int J Gynaecol Obstet; 1986 Dec; 24(6):453-7. PubMed ID: 20419910
[TBL] [Abstract][Full Text] [Related]
7. High-stage endometrioid carcinoma of the ovary. Prognostic significance of pure versus mixed histologic types.
Tornos C; Silva EG; Khorana SM; Burke TW
Am J Surg Pathol; 1994 Jul; 18(7):687-93. PubMed ID: 8017563
[TBL] [Abstract][Full Text] [Related]
8. The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer.
Chen S; Dai X; Gao Y; Shen F; Ding J; Chen Q
Sci Rep; 2017 Dec; 7(1):16922. PubMed ID: 29208958
[TBL] [Abstract][Full Text] [Related]
9. Hormone receptors and ovarian cancer survival.
Gourley C
Lancet Oncol; 2013 Aug; 14(9):794-5. PubMed ID: 23845224
[No Abstract] [Full Text] [Related]
10. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
[TBL] [Abstract][Full Text] [Related]
11. Endometrioid Carcinoma of the Ovary: Outcomes Compared to Serous Carcinoma After 10 Years of Follow-Up.
Bouchard-Fortier G; Panzarella T; Rosen B; Chapman W; Gien LT
J Obstet Gynaecol Can; 2017 Jan; 39(1):34-41. PubMed ID: 28062021
[TBL] [Abstract][Full Text] [Related]
12. Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma.
Fujimura M; Hidaka T; Kataoka K; Yamakawa Y; Akada S; Teranishi A; Saito S
Am J Surg Pathol; 2001 May; 25(5):667-72. PubMed ID: 11342781
[TBL] [Abstract][Full Text] [Related]
13. HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up.
Geisler JP; Tammela JE; Manahan KJ; Geisler HE; Miller GA; Zhou Z; Wiemann MC
Eur J Gynaecol Oncol; 2004; 25(2):165-8. PubMed ID: 15032273
[TBL] [Abstract][Full Text] [Related]
14. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma.
Al-Hussaini M; Stockman A; Foster H; McCluggage WG
Histopathology; 2004 Feb; 44(2):109-15. PubMed ID: 14764054
[TBL] [Abstract][Full Text] [Related]
15. GATA6: a new predictor for prognosis in ovarian cancer.
Shen W; Niu N; Lawson B; Qi L; Zhang J; Li T; Zhang H; Liu J
Hum Pathol; 2019 Apr; 86():163-169. PubMed ID: 30633927
[TBL] [Abstract][Full Text] [Related]
16. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
17. Role of WT1, B-cell lymphoma 2, Ki-67 (Mib1), and Her2/Neu as diagnostic and prognostic immunomarkers in ovarian serous and endometroid carcinoma.
Mondal SK; Basak B; Bhattacharya S; Panda UK
J Cancer Res Ther; 2021; 17(1):164-169. PubMed ID: 33723149
[TBL] [Abstract][Full Text] [Related]
18. Progesterone reduces cell survival in primary cultures of endometrioid ovarian cancer.
Pedernera E; Gómora MJ; Morales-Vásquez F; Pérez-Montiel D; Mendez C
J Ovarian Res; 2019 Feb; 12(1):15. PubMed ID: 30736825
[TBL] [Abstract][Full Text] [Related]
19. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
20. Mesonephric-like Differentiation of Ovarian Endometrioid and High-grade Serous Carcinomas: Clinicopathological and Molecular Characteristics Distinct from Those of Mesonephric-like Adenocarcinoma.
Choi KH; Kim H; Bae GE; Lee SH; Woo HY; Kim HS
Anticancer Res; 2021 Sep; 41(9):4587-4601. PubMed ID: 34475087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]